Pharmaceutical policy and off‐label prescribing in pregnancy: A population‐based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme
Acta Obstetricia et Gynecologica Scandinavica · 2026-09 · 105 (9) · 1789-1799
DOI: 10.1111/aogs.70283 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, online erschienen am 11.06.2026. Verfasst von Hannah Jackson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, School of Public Health, University of Technology Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Antiemetics, Off-Label Use, Healthcare Disparities, Health Services Accessibility. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Channel 7 Children's Research Foundation, Australian Government Research Training Program Stipend.
Abstract (Originalsprache)
Introduction
Nausea and vomiting in pregnancy is highly prevalent and can significantly impact pregnant women's quality of life. Despite this, access to effective pharmacotherapies can be constrained by stringent regulatory controls and socioeconomic barriers. The objective of this study was to examine the socioeconomic distribution of antiemetics (metoclopramide, ondansetron, and prochlorperazine) dispensed to pregnant women through Australia's publicly subsidized Pharmaceutical Benefits Scheme. Material and Methods We used the Maternity1000 linked administrative dataset to characterize antiemetics dispensed during 297 630 pregnancies in Queensland, Australia (July 2013 to June 2018). Using a population‐based historical cohort study design, we analyzed dispensing volume, prevalence, and government expenditure across socioeconomic quintiles, with socioeconomic disadvantage defined using the Australian Bureau of Statistics' Index of Relative Socioeconomic Disadvantage. Inequalities in medication access and public expenditure were assessed using concentration indices (C) and concentration curves.
Results
Off‐label ondansetron dispensings for nausea and vomiting in pregnancy (i.e., use outside Therapeutic Goods Administration‐approved indications and not subsidized under the Pharmaceutical Benefits Scheme) accounted for the largest share of public expenditure (53.5%), followed by metoclopramide (45.2%) and prochlorperazine (1.3%). Across all three antiemetics, prevalence was highest among women in the most socioeconomically disadvantaged quintiles and declined progressively across the two least disadvantaged groups. Small pro‐poor inequalities in access (C < −0.10) and moderate pro‐poor inequalities in public expenditure (C > −0.25) were observed across all antiemetics. (Medication access: C metoclopramide = −0.07, 95% CI (−0.080 to −0.068); C ondansetron = −0.09, 95% CI (−0.114 to −0.075); C prochlorperazine = −0.08, 95% CI (−0.109 to −0.045). Government expenditure: C metoclopramide = −0.30, 95% CI (−0.316 to −0.285); C ondansetron = −0.25, 95% CI (−0.297 to −0.198); C prochlorperazine = −0.28, 95% CI (−0.350 to −0.205)).
Conclusions
Off‐label ondansetron access accounted for the majority of public expenditure on antiemetics dispensed during pregnancy, revealing a disconnect between health policy, clinical practice, public expenditure, and pregnant women's needs. While pro‐poor access and public subsidies for antiemetics align with the equity elements embedded in the design of the Pharmaceutical Benefits Scheme, they may also be reflective of inequitable access to other unsubsidized, guideline‐recommended pharmacotherapies for nausea and vomiting in pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Health, School of Public Health, University of Technology Sydney, Sydney, New South Wales, Australia.
- College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
- SAHMRI Women and Kids, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
- Monash Centre for Health Research and Implementation (MCHRI), Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
ORCID-Profile: Hannah Jackson, Luke Grzeskowiak, Joanne Enticott, Sarah Wise, Emily Callander
Förderung
- National Health and Medical Research Council
- Channel 7 Children's Research Foundation
- Australian Government Research Training Program Stipend
Zitieren
APA
Jackson, H., Grzeskowiak, L., Enticott, J., Wise, S., & Callander, E. (2026). Pharmaceutical policy and off‐label prescribing in pregnancy: A population‐based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme. Acta Obstetricia et Gynecologica Scandinavica, 105(9), 1789-1799. https://doi.org/10.1111/aogs.70283
Vancouver
Jackson H, Grzeskowiak L, Enticott J, Wise S, Callander E. Pharmaceutical policy and off‐label prescribing in pregnancy: A population‐based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme. Acta Obstetricia et Gynecologica Scandinavica. 2026;105(9):1789-1799. doi:10.1111/aogs.70283
BibTeX
@article{Jackson2026,
author = {Jackson, Hannah and Grzeskowiak, Luke and Enticott, Joanne and Wise, Sarah and Callander, Emily},
title = {Pharmaceutical policy and off‐label prescribing in pregnancy: A population‐based historical cohort study analyzing inequality in access to antiemetics within Australia's Pharmaceutical Benefits Scheme},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2026},
volume = {105},
number = {9},
pages = {1789--1799},
doi = {10.1111/aogs.70283}
}
EUVIMED